Autopsy report · NCT01496430

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

“Business Decision; No Safety Or Efficacy Concerns. (See below)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 105 participants enrolled.
• Results were posted on the registry 2 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Takeda

Sponsor type

Industry

Conditions

Hypertension; Diabetes

Interventions

Placebo; Azilsartan medoxomil; Azilsartan medoxomil

Participants

105

Sites

68

Countries

United States

Trials that died the same way

• MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
  “Business Decision; No Safety Or Efficacy Concerns.” (95% match in meaning)
• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (82% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (79% match in meaning)
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
  “Business decision, insufficient enrollment, no safety or efficacy concerns.” (78% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.